Evgeniy M. Shilov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Evgeniy M. Shilov has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
N L Kozlovskaia
11 shared publications- Sona S. Allazova
Sechenov First Moscow State Medical University
10 shared publications - Oleg N. Kotenko
Pirogov Russian National Research Medical University; Moscow Clinical Research Center Hospital No. 52 of the Moscow Department of Health
9 shared publications - Dmitry Aleksandrovich Zateyshchikov
Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation; Bauman City Clinical Hospital No. 29 of the Moscow Department of Health
7 shared publications - Larisa Olegovna Minushkina
Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation
7 shared publications N G Miroshnichenko
7 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Sechenov University in National Health Care (Russia)
- Vol. 7 (2) , 39-51
Diabetes mellitus before and after kidney transplantation: five-year outcomes and organizational priorities in the late post-transplant period
Aim. To assess temporal trends in the proportion of diabetic kidney disease as the primary cause of end-stage kidney disease among kidney transplant recipients, compare 5-year clinical outcomes according to diabetes mellitus status, and identify priorities for long-term post-transplant care. Materials and methods. This single-center retrospective observational study included 2,146 adult kidney transplant recipients who underwent kidney transplantation between 1989 and 2018; temporal trends were examined across five consecutive 6-year periods. Five-year outcomes were assessed in 851 recipients who underwent isolated kidney transplantation between 2013 and 2018. Recipients with pre-existing diabetes mellitus were compared with those without diabetes at transplantation. Additional analyses included four phenotypic groups: type 1 diabetes mellitus, type 2 diabetes mellitus, post-transplant diabetes mellitus, and no diabetes mellitus. Results. The proportion of diabetic kidney disease as the primary cause of end-stage kidney disease increased from 0% in 1989–1994 to 13.8% in 2007–2012 and was 10.8% in 2013–2018. A significant increasing trend was observed for type 2 diabetes mellitus (p < 0.001). Pre-existing diabetes mellitus was present in 88 recipients (10.3%). Five-year all-cause mortality was higher among recipients with pre-existing diabetes mellitus than among those without diabetes at transplantation (30.7% vs. 8.0%; relative risk, 3.84; 95% confidence interval, 2.58–5.70). Composite cardiovascular events were also more frequent (12.5% vs. 4.8%; relative risk, 2.58; 95% confidence interval, 1.36–4.87). The incidence of the composite kidney outcome was similar between groups (8.0% vs. 7.6%; p = 0.906). Post-transplant diabetes mellitus developed in 80 of 763 recipients without diabetes at transplantation (10.5%). The incidence of de novo malignancy and infection-related mortality did not differ significantly between groups. A functioning kidney allograft was present at death in 87.5% of deceased recipients. Conclusion. Pre-existing diabetes mellitus was associated with higher all-cause mortality and a greater burden of cardiovascular events, while kidney outcomes were similar. These findings support a nephrologist-coordinated multidisciplinary long-term follow-up model integrating endocrinology and cardiovascular care, systematic screening for post-transplant diabetes mellitus, infection prevention, and cancer surveillance.
- 19 October 2026
- Published by Sechenov University in National Health Care (Russia)
- Vol. 7 (2) , 39-51
Open AccessDiabetes mellitus before and after kidney transplantation: five-year outcomes and organizational priorities in the late post-transplant period
Aim. To assess temporal trends in the proportion of diabetic kidney disease as the primary cause of end-stage kidney disease among kidney transplant recipients, compare 5-year clinical outcomes according to diabetes mellitus status, and identify priorities for long-term post-transplant care. Materials and methods. This single-center retrospective observational study included 2,146 adult kidney transplant recipients who underwent kidney transplantation between 1989 and 2018; temporal trends were examined across five consecutive 6-year periods. Five-year outcomes were assessed in 851 recipients who underwent isolated kidney transplantation between 2013 and 2018. Recipients with pre-existing diabetes mellitus were compared with those without diabetes at transplantation. Additional analyses included four phenotypic groups: type 1 diabetes mellitus, type 2 diabetes mellitus, post-transplant diabetes mellitus, and no diabetes mellitus. Results. The proportion of diabetic kidney disease as the primary cause of end-stage kidney disease increased from 0% in 1989–1994 to 13.8% in 2007–2012 and was 10.8% in 2013–2018. A significant increasing trend was observed for type 2 diabetes mellitus (p < 0.001). Pre-existing diabetes mellitus was present in 88 recipients (10.3%). Five-year all-cause mortality was higher among recipients with pre-existing diabetes mellitus than among those without diabetes at transplantation (30.7% vs. 8.0%; relative risk, 3.84; 95% confidence interval, 2.58–5.70). Composite cardiovascular events were also more frequent (12.5% vs. 4.8%; relative risk, 2.58; 95% confidence interval, 1.36–4.87). The incidence of the composite kidney outcome was similar between groups (8.0% vs. 7.6%; p = 0.906). Post-transplant diabetes mellitus developed in 80 of 763 recipients without diabetes at transplantation (10.5%). The incidence of de novo malignancy and infection-related mortality did not differ significantly between groups. A functioning kidney allograft was present at death in 87.5% of deceased recipients. Conclusion. Pre-existing diabetes mellitus was associated with higher all-cause mortality and a greater burden of cardiovascular events, while kidney outcomes were similar. These findings support a nephrologist-coordinated multidisciplinary long-term follow-up model integrating endocrinology and cardiovascular care, systematic screening for post-transplant diabetes mellitus, infection prevention, and cancer surveillance.
- Open Access
- 23 September 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (10S) , 7111
Results of a prospective, observational, multicenter study of patients with hypertension and chronic kidney disease in the Russian Federation (PRIORITY-CKD)
Aim. To assess the incidence of chronic kidney disease (CKD) in adult patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characteristics and treatment options in the overall cohort and a subgroup with verified CKD. Material and methods. PRIORITY-CKD is a multicenter, observational, prospective study with a retrospective analysis of patients with hypertension and markers of CKD in the Russian Federation. The study design has been described in detail previously. Results. The analytical cohort included 9914 patients. The diagnosis of CKD was confirmed in 8430 (85%) patients with HTN and CKD markers during the study as follows: 3795 (38,3%) at Visit 1 and 4635 (46,8%) at Visit 2. The estimated glomerular filtration rate was used as diagnostic criteria in 8406 (97,4%) cases. Albuminuria/proteinuria and a combination of markers were used in 13 (0,2%) and 11 (0,1%) patients, respectively. In the overall cohort and the subgroup with verified CKD, women predominated, the median duration of hypertension was similar and amounted to 10 years. More than half of the patients had stage III hypertension and the very high cardiovascular risk category. A high frequency of metabolic risk factors (overweight, abdominal obesity, dyslipidemia) and coronary artery disease (33%/34,9% in the two cohorts, respectively) was observed. Uncontrolled blood pressure (BP) (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg while receiving antihypertensive therapy (AHT)) and signs of AHT resistance were detected in 36,0% and 6,0% of patients in the overall cohort, respectively, and in the same proportion of patients in the CKD subgroup. Combination AHT was received by 72,3% of patients in the study cohort after Visit 1. After CKD diagnosis was confirmed, sodium-glucose cotransporter type 2 inhibitors were prescribed in 31,1% of cases. Conclusion. In the Russian population, CKD was confirmed in 85% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. A high frequency of uncontrolled HTN, a significant burden of metabolic risk factors, and cardiovascular disease were observed in the overall cohort and the CKD subgroup. The incremental use of renoprotective therapy after verification of the CKD diagnosis was insufficient.
- 23 September 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (10S) , 7111
Open AccessResults of a prospective, observational, multicenter study of patients with hypertension and chronic kidney disease in the Russian Federation (PRIORITY-CKD)
Aim. To assess the incidence of chronic kidney disease (CKD) in adult patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characteristics and treatment options in the overall cohort and a subgroup with verified CKD. Material and methods. PRIORITY-CKD is a multicenter, observational, prospective study with a retrospective analysis of patients with hypertension and markers of CKD in the Russian Federation. The study design has been described in detail previously. Results. The analytical cohort included 9914 patients. The diagnosis of CKD was confirmed in 8430 (85%) patients with HTN and CKD markers during the study as follows: 3795 (38,3%) at Visit 1 and 4635 (46,8%) at Visit 2. The estimated glomerular filtration rate was used as diagnostic criteria in 8406 (97,4%) cases. Albuminuria/proteinuria and a combination of markers were used in 13 (0,2%) and 11 (0,1%) patients, respectively. In the overall cohort and the subgroup with verified CKD, women predominated, the median duration of hypertension was similar and amounted to 10 years. More than half of the patients had stage III hypertension and the very high cardiovascular risk category. A high frequency of metabolic risk factors (overweight, abdominal obesity, dyslipidemia) and coronary artery disease (33%/34,9% in the two cohorts, respectively) was observed. Uncontrolled blood pressure (BP) (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg while receiving antihypertensive therapy (AHT)) and signs of AHT resistance were detected in 36,0% and 6,0% of patients in the overall cohort, respectively, and in the same proportion of patients in the CKD subgroup. Combination AHT was received by 72,3% of patients in the study cohort after Visit 1. After CKD diagnosis was confirmed, sodium-glucose cotransporter type 2 inhibitors were prescribed in 31,1% of cases. Conclusion. In the Russian population, CKD was confirmed in 85% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. A high frequency of uncontrolled HTN, a significant burden of metabolic risk factors, and cardiovascular disease were observed in the overall cohort and the CKD subgroup. The incremental use of renoprotective therapy after verification of the CKD diagnosis was insufficient.
- Open Access
- 23 September 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (10S) , 7130
Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee
Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee | Shlyakhto | Russian Journal of Cardiology Согласительные междисциплинарные позиции наблюдательного комитета по метаболическому синдрому | Шляхто | Российский кардиологический журнал
- 23 September 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (10S) , 7130
Open AccessConsensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee
Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee | Shlyakhto | Russian Journal of Cardiology Согласительные междисциплинарные позиции наблюдательного комитета по метаболическому синдрому | Шляхто | Российский кардиологический журнал
- Open Access
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 89-130
Follow-up monitoring of patients with chronic kidney disease by primary care physicians. Guidelines
The high and steadily increasing prevalence of chronic kidney disease (CKD) is a significant medical and social problem. CKD complications significantly reduce quality of life and increase the risk of disability, hospitalization, and death. Timely identification and correction of modifiable risk factors for CKD progression underpins secondary prevention measures. These guidelines describe the management of follow-up monitoring for CKD patients by a general practitioner and incorporate modern approaches to diagnosing disease severity and complications (clinical and paraclinical methods), as well as disease treatment and complication prevention. Application of these guidelines will enable physicians to make informed clinical decisions based on the presented diagnostic algorithm (examinations, consultations). These guidelines are intended for general practitioners, family doctors, and for nursing staff working with these physicians, for paramedics performing the doctor functions of managing follow-up monitoring. These guidelines are also intended for healthcare executives, heads of primary care facilities, and their departments.
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 89-130
Open AccessFollow-up monitoring of patients with chronic kidney disease by primary care physicians. Guidelines
The high and steadily increasing prevalence of chronic kidney disease (CKD) is a significant medical and social problem. CKD complications significantly reduce quality of life and increase the risk of disability, hospitalization, and death. Timely identification and correction of modifiable risk factors for CKD progression underpins secondary prevention measures. These guidelines describe the management of follow-up monitoring for CKD patients by a general practitioner and incorporate modern approaches to diagnosing disease severity and complications (clinical and paraclinical methods), as well as disease treatment and complication prevention. Application of these guidelines will enable physicians to make informed clinical decisions based on the presented diagnostic algorithm (examinations, consultations). These guidelines are intended for general practitioners, family doctors, and for nursing staff working with these physicians, for paramedics performing the doctor functions of managing follow-up monitoring. These guidelines are also intended for healthcare executives, heads of primary care facilities, and their departments.
- Open Access
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 374-386
"School" for patients receiving chronic hemodialysis therapy. Guidelines
Chronic kidney disease (CKD) develops as a result of a gradual and irreversible decline in kidney function caused by various factors. Patients with end-stage renal failure undergo long-term or lifelong renal replacement therapy — chronic hemodialysis. Patients on chronic hemodialysis are at high risk, the main ones being cardiovascular events, strokes, infections associated with vascular access (fistula) or peritoneal catheters, as well as anemia, mineral metabolism disorders, and intradialytic hypotension. Educating patients on chronic hemodialysis through patient "schools" plays an important role in improving their quality of life and reducing the risk of complications associated with both the hemodialysis process itself and end-stage CKD. The guidelines for managing "school" for patients on chronic hemodialysis contain general information about the disease, organize and conduction of patient "schools", recommended topics and lesson content, and tests for assessing patient knowledge. The guidelines are intended for specialists who meet the qualification requirements for medical and pharmaceutical workers with secondary vocational education in General Medicine or Nursing, as well as for primary care physicians involved in conducting patient "schools".
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 374-386
Open Access"School" for patients receiving chronic hemodialysis therapy. Guidelines
Chronic kidney disease (CKD) develops as a result of a gradual and irreversible decline in kidney function caused by various factors. Patients with end-stage renal failure undergo long-term or lifelong renal replacement therapy — chronic hemodialysis. Patients on chronic hemodialysis are at high risk, the main ones being cardiovascular events, strokes, infections associated with vascular access (fistula) or peritoneal catheters, as well as anemia, mineral metabolism disorders, and intradialytic hypotension. Educating patients on chronic hemodialysis through patient "schools" plays an important role in improving their quality of life and reducing the risk of complications associated with both the hemodialysis process itself and end-stage CKD. The guidelines for managing "school" for patients on chronic hemodialysis contain general information about the disease, organize and conduction of patient "schools", recommended topics and lesson content, and tests for assessing patient knowledge. The guidelines are intended for specialists who meet the qualification requirements for medical and pharmaceutical workers with secondary vocational education in General Medicine or Nursing, as well as for primary care physicians involved in conducting patient "schools".
- 26 January 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 29 (4)
Chronic kidney disease should become a priority area of russian healthcare. Statement by the Presidium of the Specialized Commission on Nephrology of the Ministry of Health of the Russian Federation
Chronic kidney disease (CKD) is the fifth globally socially significant chronic non–communicable disease recognized by WHO. The prevalence of CKD in the world ranges from 10 to 20 % and outstrips the prevalence of diabetes mellitus and cardiovascular diseases (850, 600, and 560 million people, respectively). By 2040, CKD will become the 5th cause of premature mortality, ahead of cancer and diabetes mellitus. In Russia, the prevalence of CKD in risk groups (hypertension, chronic heart failure, and diabetes mellitus) is at least 16 % of the country's population. CKD significantly increases the medical, social, and financial burden on the state budget, a significant part of which is spent on saving the lives of patients who have survived to the end stage renal disease, such as kidney replacement therapy (dialysis, kidney transplantation) and treatment of comorbid conditions. CKD makes a huge contribution to premature mortality. Most patients die from cardiovascular complications (strokes, heart attacks, heart failure) before the development of the terminal stage of the disease. Early detection of the disease will improve the ability to work and enhance the quality of life, as well as increase its duration. Special attention should be paid to risk groups, primarily patients with cardiovascular diseases and diabetes mellitus. The current management strategy for CKD patients is prevention and screening for early manifestations of CKD (decreased glomerular filtration rate and albuminuria), followed by the use of triple cardio–reno-protective therapy (RAAS inhibitors, glyphlozines, synthetic mineralocorticoid receptor blockers), which can slow the progression to the terminal stage of the disease and reduce mortality from cardiovascular complications. Preserving and prolonging the lives of CKD patients requires appropriate government organizational measures – in essence, changing the existing healthcare model focused on the terminal stages of the disease to a model aimed at prevention, early detection, and slowing the progression of CKD
- 26 January 2026
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 29 (4)
Chronic kidney disease should become a priority area of russian healthcare. Statement by the Presidium of the Specialized Commission on Nephrology of the Ministry of Health of the Russian Federation
Chronic kidney disease (CKD) is the fifth globally socially significant chronic non–communicable disease recognized by WHO. The prevalence of CKD in the world ranges from 10 to 20 % and outstrips the prevalence of diabetes mellitus and cardiovascular diseases (850, 600, and 560 million people, respectively). By 2040, CKD will become the 5th cause of premature mortality, ahead of cancer and diabetes mellitus. In Russia, the prevalence of CKD in risk groups (hypertension, chronic heart failure, and diabetes mellitus) is at least 16 % of the country's population. CKD significantly increases the medical, social, and financial burden on the state budget, a significant part of which is spent on saving the lives of patients who have survived to the end stage renal disease, such as kidney replacement therapy (dialysis, kidney transplantation) and treatment of comorbid conditions. CKD makes a huge contribution to premature mortality. Most patients die from cardiovascular complications (strokes, heart attacks, heart failure) before the development of the terminal stage of the disease. Early detection of the disease will improve the ability to work and enhance the quality of life, as well as increase its duration. Special attention should be paid to risk groups, primarily patients with cardiovascular diseases and diabetes mellitus. The current management strategy for CKD patients is prevention and screening for early manifestations of CKD (decreased glomerular filtration rate and albuminuria), followed by the use of triple cardio–reno-protective therapy (RAAS inhibitors, glyphlozines, synthetic mineralocorticoid receptor blockers), which can slow the progression to the terminal stage of the disease and reduce mortality from cardiovascular complications. Preserving and prolonging the lives of CKD patients requires appropriate government organizational measures – in essence, changing the existing healthcare model focused on the terminal stages of the disease to a model aimed at prevention, early detection, and slowing the progression of CKD
- Open Access
- 23 October 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (9) , 10-18
Efficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study
Aim To evaluate the safety and efficacy of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) inhibitor therapy in kidney transplant recipients (KTRs) with and without post-transplant diabetes mellitus (PTDM). Material and methods KTRs (n=2146, with PTDM n=303, or 14%) who had undergone transplantation more than one year ago, with stable graft function (estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2), after excluding patients with combined kidney and pancreas transplantation (n=57), type 1 diabetes mellitus (DM) (n=124), and type 2 DM diagnosed before kidney allotransplantation (KAT) (n=74), were prescribed SGLT-2i (empagliflozin 25 mg/day or dapagliflozin 10 mg/day; n=107), the rest of the KTRs (n=1784) did not receive SGLT-2i. After pseudo-randomization, two groups were formed and included in an open, single-center prospective study: an experimental group with SGLT-2i (n=78; with PTDM n=45) and a control group, without SGLT-2i (n=78; n=45 with PTDM). The groups were comparable in the PTDM duration and the period from KAT to inclusion in the study, as well as in clinical characteristics, including gender, age, history of acute myocardial infarction (AMI) before KAT, levels of glycated hemoglobin (HbA1c), systolic blood pressure (SBP) and diastolic blood pressure (DBP), GFR, microalbuminuria (MAU), blood uric acid concentration, blood lipid profile (total cholesterol (TC), low-density lipoproteins (LDL)), basal blood concentration (C0) of calcineurin inhibitors (CNI), and therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), statins, and metformin (p >0.05). Results The relative risk (RR) of all-cause death in the experimental group was reduced by 60% compared with the control group (RR 0.40; 95% confidence interval (CI) 0.17-0.98 vs. RR 2.44; 95% CI 1.01-5.86; p=0.04). The RR of adverse coronary outcomes in the experimental group was reduced by 75% compared with the control group (RR 0.25; 95% CI 0.06-0.89 vs. 4.0; 95% CI 1.11-14.42; p=0.03). The RR of adverse renal outcomes in the experimental group was reduced by 72% compared with the control group (RR 0.28; 95% CI 0.09-0.85 vs. 3.50; 95% CI 1.16-10.49; p=0.02). In addition, in the experimental group, compared to the control group, the GFR decline was slower (-1.29±0.763 ml/min/1.73 m2/year vs. -3.33±0.767 ml/min/1.73 m2/year; p=0.047). Also, a pronounced advantage in the dynamic decline in GFR was observed throughout the entire study period (-3.10±1.73 ml/min/1.73 m2 vs. -7.87±1.87 ml/min/1.73 m2; p=0.040). Conclusion SGLT2i effectively reduce cardiovascular and renal mortality, the risk of adverse renal and coronary outcomes, and slow the progression of chronic kidney disease in KTRs, regardless of the presence of PTDM. A large-scale study evaluating the efficacy of SGLT2i in KTRs is warranted to formulate appropriate clinical recommendations.
- 23 October 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (9) , 10-18
Open AccessEfficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study
Aim To evaluate the safety and efficacy of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) inhibitor therapy in kidney transplant recipients (KTRs) with and without post-transplant diabetes mellitus (PTDM). Material and methods KTRs (n=2146, with PTDM n=303, or 14%) who had undergone transplantation more than one year ago, with stable graft function (estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2), after excluding patients with combined kidney and pancreas transplantation (n=57), type 1 diabetes mellitus (DM) (n=124), and type 2 DM diagnosed before kidney allotransplantation (KAT) (n=74), were prescribed SGLT-2i (empagliflozin 25 mg/day or dapagliflozin 10 mg/day; n=107), the rest of the KTRs (n=1784) did not receive SGLT-2i. After pseudo-randomization, two groups were formed and included in an open, single-center prospective study: an experimental group with SGLT-2i (n=78; with PTDM n=45) and a control group, without SGLT-2i (n=78; n=45 with PTDM). The groups were comparable in the PTDM duration and the period from KAT to inclusion in the study, as well as in clinical characteristics, including gender, age, history of acute myocardial infarction (AMI) before KAT, levels of glycated hemoglobin (HbA1c), systolic blood pressure (SBP) and diastolic blood pressure (DBP), GFR, microalbuminuria (MAU), blood uric acid concentration, blood lipid profile (total cholesterol (TC), low-density lipoproteins (LDL)), basal blood concentration (C0) of calcineurin inhibitors (CNI), and therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), statins, and metformin (p >0.05). Results The relative risk (RR) of all-cause death in the experimental group was reduced by 60% compared with the control group (RR 0.40; 95% confidence interval (CI) 0.17-0.98 vs. RR 2.44; 95% CI 1.01-5.86; p=0.04). The RR of adverse coronary outcomes in the experimental group was reduced by 75% compared with the control group (RR 0.25; 95% CI 0.06-0.89 vs. 4.0; 95% CI 1.11-14.42; p=0.03). The RR of adverse renal outcomes in the experimental group was reduced by 72% compared with the control group (RR 0.28; 95% CI 0.09-0.85 vs. 3.50; 95% CI 1.16-10.49; p=0.02). In addition, in the experimental group, compared to the control group, the GFR decline was slower (-1.29±0.763 ml/min/1.73 m2/year vs. -3.33±0.767 ml/min/1.73 m2/year; p=0.047). Also, a pronounced advantage in the dynamic decline in GFR was observed throughout the entire study period (-3.10±1.73 ml/min/1.73 m2 vs. -7.87±1.87 ml/min/1.73 m2; p=0.040). Conclusion SGLT2i effectively reduce cardiovascular and renal mortality, the risk of adverse renal and coronary outcomes, and slow the progression of chronic kidney disease in KTRs, regardless of the presence of PTDM. A large-scale study evaluating the efficacy of SGLT2i in KTRs is warranted to formulate appropriate clinical recommendations.
- Open Access
- 10 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (11S) , 6515
Interim analysis of prospective observational multicenter study of patients with hypertension and chronic kidney disease in the Russian Federation (PRIORITY-CKD)
Aim. To describe the detection rate of chronic kidney disease (CKD) in patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characteristics and features of therapy in the overall cohort and a subgroup with verified CKD.Material and methods. The article presents an interim analysis of data from a prospective observational multicenter study of patients with HTN and CKD in the Russian Federation (PRIORITY-CKD).Results. Data from the first 3249 patients included in the study were analyzed. In 2592 (79,8%) patients with HTN and CKD markers, the diagnosis of CKD was confirmed during the study as follows: in 1380 (42,5%) at Visit 1 and in 1212 (37,3%) at Visit 2. In 2488 (96%) cases, only the estimated glomerular filtration rate was used as the criteria for the diagnosis of CKD. Only in 12 patients (0,5%) albuminuria or proteinuria (alone or together with other CKD markers) was used as diagnostic criteria for CKD diagnosis. Cases of overdiagnosis (12,6%) and underdiagnosis (0,4%) of CKD were identified. In the overall cohort and the subgroup with verified CKD, women predominated (61,6/62,1%), while the median duration of HTN was 9 and 10 years, respectively. More than half of the patients had stage III HTN and very high cardiovascular risk. A high rate of metabolic risk factors (overweight, dyslipidemia, abdominal obesity) and atherosclerotic cardiovascular diseases was noted. Coronary artery disease was observed in a third of patients in the overall cohort and the CKD subgroup. Uncontrolled HTN (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg despite antihypertensive therapy) and resistant HTN were detected in 42,5% and 6,7% of patients in the overall cohort, while in the subgroup with CKD in 42,1% and 7,3%, respectively. Combination antihypertensive therapy after Visit 1 was received by 78,8% of patients in the examined cohort. Only in 21,4% of cases, sodium-glucose cotransporter-2 inhibitors were prescribed after verification of the CKD diagnosis.Conclusion. In the Russian population, the diagnosis of CKD was confirmed in 79,8% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. Cases of overdiagnosis and underdiagnosis of CKD were identified. A high rate of uncontrolled HTN and a serious burden of atherosclerotic cardiovascular diseases were observed in the overall cohort and the subgroup with CKD. After CKD verification, a suboptimal increase in the prescription of sodiumglucose cotransporter-2 inhibitors was noted.
- 10 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (11S) , 6515
Open AccessInterim analysis of prospective observational multicenter study of patients with hypertension and chronic kidney disease in the Russian Federation (PRIORITY-CKD)
Aim. To describe the detection rate of chronic kidney disease (CKD) in patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characteristics and features of therapy in the overall cohort and a subgroup with verified CKD.Material and methods. The article presents an interim analysis of data from a prospective observational multicenter study of patients with HTN and CKD in the Russian Federation (PRIORITY-CKD).Results. Data from the first 3249 patients included in the study were analyzed. In 2592 (79,8%) patients with HTN and CKD markers, the diagnosis of CKD was confirmed during the study as follows: in 1380 (42,5%) at Visit 1 and in 1212 (37,3%) at Visit 2. In 2488 (96%) cases, only the estimated glomerular filtration rate was used as the criteria for the diagnosis of CKD. Only in 12 patients (0,5%) albuminuria or proteinuria (alone or together with other CKD markers) was used as diagnostic criteria for CKD diagnosis. Cases of overdiagnosis (12,6%) and underdiagnosis (0,4%) of CKD were identified. In the overall cohort and the subgroup with verified CKD, women predominated (61,6/62,1%), while the median duration of HTN was 9 and 10 years, respectively. More than half of the patients had stage III HTN and very high cardiovascular risk. A high rate of metabolic risk factors (overweight, dyslipidemia, abdominal obesity) and atherosclerotic cardiovascular diseases was noted. Coronary artery disease was observed in a third of patients in the overall cohort and the CKD subgroup. Uncontrolled HTN (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg despite antihypertensive therapy) and resistant HTN were detected in 42,5% and 6,7% of patients in the overall cohort, while in the subgroup with CKD in 42,1% and 7,3%, respectively. Combination antihypertensive therapy after Visit 1 was received by 78,8% of patients in the examined cohort. Only in 21,4% of cases, sodium-glucose cotransporter-2 inhibitors were prescribed after verification of the CKD diagnosis.Conclusion. In the Russian population, the diagnosis of CKD was confirmed in 79,8% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. Cases of overdiagnosis and underdiagnosis of CKD were identified. A high rate of uncontrolled HTN and a serious burden of atherosclerotic cardiovascular diseases were observed in the overall cohort and the subgroup with CKD. After CKD verification, a suboptimal increase in the prescription of sodiumglucose cotransporter-2 inhibitors was noted.
- Open Access
- 11 August 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (6) , 4466
Cardiovascular risk and chronic kidney disease: strategies for cardiac and renal protection. Interdisciplinary consensus
The consensus was developed by experts from the Russian Scientific Medical Society of Internal Medicine, the Russian Society for the Prevention of Noncommunicable Diseases, the National Nephrology Association, the Professional Nephrology Association, the Russian Society of Cardiology, the Russian Medical Society for Arterial Hypertension, the Heart Failure Society, the National Atherosclerosis Society, the Russian Endocrinology Association, and the Russian Gerontology and Geriatrics Association.The expert consensus opinion was compiled on the basis of the relevant sections of national and international clinical guidelines on chronic kidney disease, prevention and treatment of atherosclerosis, hypertension, diabetes and heart failure.
- 11 August 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (6) , 4466
Open AccessCardiovascular risk and chronic kidney disease: strategies for cardiac and renal protection. Interdisciplinary consensus
The consensus was developed by experts from the Russian Scientific Medical Society of Internal Medicine, the Russian Society for the Prevention of Noncommunicable Diseases, the National Nephrology Association, the Professional Nephrology Association, the Russian Society of Cardiology, the Russian Medical Society for Arterial Hypertension, the Heart Failure Society, the National Atherosclerosis Society, the Russian Endocrinology Association, and the Russian Gerontology and Geriatrics Association.The expert consensus opinion was compiled on the basis of the relevant sections of national and international clinical guidelines on chronic kidney disease, prevention and treatment of atherosclerosis, hypertension, diabetes and heart failure.
- 2 April 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 29 (1) , 46-55
Malignancies after kidney transplantation: results of a 34-year population-based study
BACKGROUND. Cancer is the second most common cause of mortality and morbidity in kidney transplant recipients (KTRs) after cardiovascular diseases (CVDs). KTRs have at least twice the risk of developing cancer or dying from it compared to the general population. THE AIM: to calculate the standardized incidence ratio (SIR) and mortality ratio (SMR) of malignancies in KTRs registered at Municipal Clinical Hospital № 52 of the Moscow Healthcare Department and to determine independent risk factors for MN. PATIENTS AND METHODS. From January 1, 1989 to December 31, 2023, we followed 2146 KTRs registered at Municipal Clinical Hospital №52 of the Moscow Healthcare Department, in whom 14.4 % (n=310) MN were detected. In the malignancies group, the most common were non-melanoma skin cancer (NMSC) 30.3 % (n=91) and kidney cancer 11.3 % (n=41), 37.7 % (n=117) of patients died, of which 46.2 % (n=54) died directly from this cause. RESULTS. In kidney transplant recipients, the overall risk of malignancies was approximately three times higher than in the Russian population (SIR 2.85, 95 % CI: 2.4–3.2, PCONCLUSIONS. The overall incidence of malignancies after kidney transplantation in patients registered at Municipal Clinical Hospital №52 of the Moscow Healthcare Department in 1989–2023 is almost 3 times higher than the general population incidence in the Russian Federation (overall SIR = 2.85 (95 % CI: 2.4–3.2, P<0.05). Mortality from malignancies (overall SMR = 1.3 (95 % CI: 1.1–1.4, P<0.05)) is slightly higher than the general population incidence. A possible reason for the almost twofold difference between the incidence and mortality from malignancies in the Russian Federation may be the high risk of competing causes of mortality in KTRs, especially CVDs.
- 2 April 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 29 (1) , 46-55
Malignancies after kidney transplantation: results of a 34-year population-based study
BACKGROUND. Cancer is the second most common cause of mortality and morbidity in kidney transplant recipients (KTRs) after cardiovascular diseases (CVDs). KTRs have at least twice the risk of developing cancer or dying from it compared to the general population. THE AIM: to calculate the standardized incidence ratio (SIR) and mortality ratio (SMR) of malignancies in KTRs registered at Municipal Clinical Hospital № 52 of the Moscow Healthcare Department and to determine independent risk factors for MN. PATIENTS AND METHODS. From January 1, 1989 to December 31, 2023, we followed 2146 KTRs registered at Municipal Clinical Hospital №52 of the Moscow Healthcare Department, in whom 14.4 % (n=310) MN were detected. In the malignancies group, the most common were non-melanoma skin cancer (NMSC) 30.3 % (n=91) and kidney cancer 11.3 % (n=41), 37.7 % (n=117) of patients died, of which 46.2 % (n=54) died directly from this cause. RESULTS. In kidney transplant recipients, the overall risk of malignancies was approximately three times higher than in the Russian population (SIR 2.85, 95 % CI: 2.4–3.2, PCONCLUSIONS. The overall incidence of malignancies after kidney transplantation in patients registered at Municipal Clinical Hospital №52 of the Moscow Healthcare Department in 1989–2023 is almost 3 times higher than the general population incidence in the Russian Federation (overall SIR = 2.85 (95 % CI: 2.4–3.2, P<0.05). Mortality from malignancies (overall SMR = 1.3 (95 % CI: 1.1–1.4, P<0.05)) is slightly higher than the general population incidence. A possible reason for the almost twofold difference between the incidence and mortality from malignancies in the Russian Federation may be the high risk of competing causes of mortality in KTRs, especially CVDs.